Novartis's antihypertensive Rasilez to get contraindication in EU
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended a new contraindication and warning for Novartis's first-in-class antihypertensive renin inhibitor, aliskiren (Rasilez), stating that it must not be used in patients who have experienced angioedema when taking aliskiren in the past.